Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Docket		Date Filed	2022-04-08
Court	District Court, D. Delaware	Date Terminated	2024-05-30
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Parties	OTSUKA PHARMACEUTICAL CO., LTD.
Patents	10,525,057; 10,980,803; 11,154,553; 11,344,547; 11,400,087; 7,807,680; 8,030,313; 8,338,427; 8,399,469; 8,722,679
Attorneys	A. Sasha Hoyt
Firms	Wilson Sonsini Goodrich & Rosati PC
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-08				External link to document
2022-04-08	144	Report and Recommendations	,469 (the “’469 patent”), 10,525,057 (the “’057 patent”), 10,980,803 (the “’803 patent”), 11,154,553…across seven patents. The seven patents are U.S. Patent Nos. 8,338,427 (the “’427 patent”), 8,399,469… (the “’553 patent”), 11,344,547 (the “’547 patent”), and 11,400,087 (the “’087 patent”). I held … patent, claims 1, 10, and 25; ’547 patent, claims 1, 7, and 16; ’087 patent, claims 1… the ’803 patent. 16 The ’803 patent is a continuation of the ’057 patent and shares	External link to document
2022-04-08	222	Notice of Service	Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,…Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,… Jonathan W. Steed Regarding Invalidity of U.S. Patent No. 8,399,469 [Highly Confidential], and Opening… 2022 30 May 2024 1:22-cv-00464 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Otsuka Pharmaceutical v. Mylan Laboratories: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Otsuka Pharmaceutical Co., Ltd. sued Mylan Laboratories Limited in the U.S. District Court for the District of Delaware in Civil Action No. 1:22-cv-00464. The case arose from Mylan’s abbreviated new drug application, or ANDA, for a generic version of Jynarque, Otsuka’s tolvaptan product used to slow kidney-function decline in adults with rapidly progressing autosomal dominant polycystic kidney disease, or ADPKD. The dispute centered on method-of-use and formulation-related patent rights rather than basic compound exclusivity. The public docket does not disclose a merits judgment establishing invalidity or noninfringement, and settlement terms are not publicly available. [1]

What drug and ANDA were involved in Otsuka v. Mylan?

The litigation concerned tolvaptan, marketed by Otsuka as Jynarque for ADPKD. Tolvaptan is also marketed under the Samsca brand for different indications, including clinically significant hyponatremia. Jynarque is supplied as oral tablets in 15-mg, 30-mg, 45-mg, 60-mg, and 90-mg strengths. [2]

Mylan’s ANDA challenged Otsuka’s listed patents through Paragraph IV certifications. Under the Hatch-Waxman Act, a Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Otsuka’s complaint triggered the statutory 30-month stay of FDA approval, subject to the statutory exceptions and any court order. [3]

Item	Details
Brand	Jynarque
Active ingredient	Tolvaptan
Reference company	Otsuka Pharmaceutical Co., Ltd.
Generic applicant	Mylan Laboratories Limited
Court	U.S. District Court for the District of Delaware
Case number	1:22-cv-00464
Regulatory pathway	ANDA under Hatch-Waxman
Challenge	Paragraph IV patent certifications
Principal risk	Generic entry against ADPKD indication and tablet product
Public merits outcome	No publicly reported final merits judgment identified
Settlement terms	Not publicly disclosed

What patents protect Jynarque and tolvaptan?

Jynarque’s patent estate has been built principally around therapeutic use, dosing, and product-specific protection. The original tolvaptan compound patent did not provide the principal barrier to generic entry in the 2022 litigation because compound exclusivity had substantially matured. The commercial dispute instead involved later-issued patents covering ADPKD treatment and related dosing or formulation claims.

Method-of-use patents

The most important patent category for Jynarque is the method-of-use estate. These patents generally claim administering tolvaptan to patients with ADPKD, including treatment regimens designed to slow the decline in renal function.

A method patent can remain commercially significant after compound-patent expiration when:

1. the generic label includes the patented indication;
2. the ANDA applicant is required to provide labeling for that indication;
3. the branded company can prove induced infringement; or
4. the proposed product cannot be marketed without encouraging use covered by the patent.

The analysis is highly dependent on the proposed label. A generic applicant may attempt to use a “skinny label” that removes a patented indication. That strategy is less effective where the product’s central commercial use is the patented indication or where the remaining label and promotional materials support an inducement theory.

Formulation and dosing patents

Otsuka also has relied on patents directed to the administration of tolvaptan, dose titration, and product presentation. These rights can cover the initial dose, escalation schedule, split-dose administration, or treatment protocols used to manage tolerability and safety.

The Jynarque regimen is clinically distinctive because treatment is initiated at a lower dose and titrated upward. Patients also require monitoring for liver injury. Patent claims directed to that regimen may create a stronger practical barrier than a broad indication claim if the FDA-approved label reproduces the claimed dose sequence.

Orange Book status

The FDA Orange Book identifies patents and exclusivity information submitted for approved drug products. Orange Book listings do not establish patent validity. They determine the patent-certification framework an ANDA applicant must use and can create the statutory stay after a Paragraph IV notice. [4]

The Jynarque estate should be assessed by separating:

• patents listed for the product;
• patents directed to the ADPKD indication;
• patents directed to dosing or titration;
• formulation patents;
• patents covering the active ingredient itself; and
• patents no longer relevant because they have expired or are not listed against the relevant Jynarque presentation.

Public patent databases and Orange Book entries may show different practical expiration dates because patent-term adjustment, patent-term extension, terminal disclaimers, and regulatory listing practices affect the analysis. [4][5]

When does Jynarque lose exclusivity?

Jynarque’s regulatory and patent exclusivity dates are different.

Regulatory exclusivity

Tolvaptan was previously approved as Samsca. Jynarque therefore did not receive a new chemical entity period based solely on the later ADPKD approval. The Jynarque approval nevertheless created a separate product and indication record, and Otsuka’s listed patents provided the principal post-approval barrier to ANDA approval. [2][6]

The principal regulatory restraints were:

• the 30-month stay triggered by Otsuka’s patent suit;
• any remaining unexpired Orange Book patents;
• pediatric exclusivity, if applicable; and
• FDA requirements concerning the proposed generic label and risk-management obligations.

Patent expiration

The relevant generic-entry date depends on the latest enforceable patent that covers Mylan’s product and intended label. Basic tolvaptan compound protection is not the central issue in the 2022 case. The key expiration dates are those of the later method-of-use, dosing, and formulation patents asserted against Mylan.

A definitive launch date cannot be inferred from the complaint alone. It requires the final asserted patent set, the court’s claim construction and infringement findings, and any settlement or license terms. The public record does not establish a judicially determined generic-entry date for Mylan from the cited action. [1]

What did Otsuka allege against Mylan?

Otsuka’s claims followed the standard Hatch-Waxman structure. Otsuka alleged that Mylan’s ANDA filing constituted artificial infringement under 35 U.S.C. § 271(e)(2). The asserted theories typically included:

• submission of an ANDA seeking approval of a product covered by Otsuka’s patents;
• infringement of method-of-treatment claims based on Mylan’s proposed labeling;
• infringement of dosing or regimen claims;
• potential induced infringement arising from the proposed label; and
• entitlement to an order preventing FDA approval before patent expiration.

Mylan’s defenses would ordinarily include:

• noninfringement based on the ANDA product or label;
• invalidity for lack of anticipation or obviousness;
• lack of written description or enablement;
• indefiniteness;
• prosecution-history estoppel;
• improper claim scope for a method-of-use patent; and
• a safe-harbor defense for activities reasonably related to FDA submission under 35 U.S.C. § 271(e)(1).

The case was therefore likely to turn on the precise language of the proposed label and the construction of the asserted claims. For a method patent, the question is not simply whether Mylan’s tablets contain tolvaptan. The issue is whether the ANDA product and proposed use fall within each asserted claim and whether the label would induce infringement after launch.

Which legal issues determined the generic-entry risk?

Skinny-label strategy

A skinny label could reduce exposure if Mylan removed the patented ADPKD indication or omitted a claimed dosing regimen. The strategy has limits. Courts examine the entire proposed label, including warnings, dosing instructions, clinical-use directions, and the relationship between the remaining indications and the patented use.

For Jynarque, a narrow carve-out could be commercially difficult because the ADPKD indication is the product’s main value proposition. A generic that omits the central indication may lose substantial sales, while a generic that retains it faces a higher induced-infringement risk.

Claim construction

Claim construction would likely focus on terms describing:

• the patient population with rapidly progressing ADPKD;
• the meaning of slowing kidney-function decline;
• the required dose sequence;
• duration of treatment;
• liver-monitoring or treatment-interruption requirements; and
• whether claims require particular tablet strengths or administration schedules.

Small differences in claim construction could materially affect both infringement and validity.

Obviousness

Otsuka’s strongest validity position would be a claim that combines a defined ADPKD population with a specific tolvaptan regimen supported by clinical evidence. Mylan’s strongest obviousness position would rely on prior art disclosing tolvaptan, vasopressin V2 receptor antagonism, ADPKD biology, and dose-ranging or renal-treatment studies.

The commercial strength of the patent estate depends on whether the asserted claims protect a clinically necessary regimen or merely a predictable use of a known compound.

What was the litigation status and settlement position?

The docket identifies the action as a patent case filed in the District of Delaware against Mylan Laboratories Limited. The public record does not establish a trial verdict or a final judgment invalidating the asserted patents. It also does not publicly disclose the material terms of a settlement agreement, including:

• an agreed generic-entry date;
• royalty or license payments;
• an authorized-generic arrangement;
• manufacturing restrictions;
• supply rights; or
• release provisions covering other Otsuka products.

Confidential Hatch-Waxman settlements are common. If the case terminated through settlement, the absence of public commercial terms prevents a reliable calculation of Mylan’s launch date or Otsuka’s retained market share. The case should therefore be treated as resolved or procedurally closed only to the extent shown by the final docket entry, not as a merits victory for either party. [1]

How strong is Otsuka’s Jynarque patent estate?

Otsuka’s estate has moderate-to-strong commercial relevance but is narrower than a live compound patent.

Patent-estate category	Commercial value	Generic vulnerability
Compound patent	Low by the 2022 case date	Expiration and prior approval history limit value
ADPKD method claims	High	Vulnerable to label carve-outs and inducement defenses
Dose-titration claims	High if label matches	Vulnerable to noninfringement through regimen changes
Tablet or formulation claims	Moderate	Depends on claim breadth and design-around options
Safety-monitoring claims	Variable	May be difficult to enforce without label overlap
Manufacturing claims	Low to moderate for ANDA entry	Relevant if process is necessary and difficult to design around

The estate’s practical strength comes from the combination of patents. A generic applicant may avoid one patent through a label amendment or product redesign but remain blocked by another asserted claim. Conversely, a collection of narrow method claims can be weakened if the generic can legally omit the relevant indication or dosing instruction.

What generic launch scenarios exist for Mylan?

Three launch scenarios were commercially plausible.

Launch after patent expiration

Mylan could launch after the latest enforceable patent expiration date or after an agreed date under a settlement. This is the lowest litigation-risk scenario and is common where the brand retains meaningful but finite patent protection.

Launch after a successful Paragraph IV defense

If Mylan prevailed on invalidity or noninfringement, FDA approval could proceed after resolution of the statutory stay and other regulatory requirements. A judgment against the asserted patents would improve entry prospects for other ANDA applicants facing the same estate.

At-risk launch

Mylan could launch before the ultimate expiration of the asserted patents after a favorable litigation ruling or absent an effective injunction. An at-risk launch could expose Mylan to damages, enhanced damages in exceptional circumstances, and potential market disruption. It would also create collateral risk for wholesalers, pharmacies, and payers if the patent position were later reinstated.

How does Jynarque compare with Samsca for patent risk?

Jynarque and Samsca contain the same active ingredient but have different commercial and patent profiles.

Issue	Jynarque	Samsca
Active ingredient	Tolvaptan	Tolvaptan
Principal use	ADPKD	Hyponatremia and related uses
Commercial patent focus	ADPKD methods, dosing, formulation	Earlier product and indication rights
Liver-monitoring burden	Central to label	Different safety and duration profile
Generic strategy	Label carve-out is commercially difficult	Indication-specific substitution may be easier
Litigation relevance	Main subject of the 2022 Otsuka-Mylan case	Separate patent and regulatory analysis required

The shared active ingredient does not make the products interchangeable for patent purposes. Different indications, dosage regimens, labels, and risk controls can produce separate infringement analyses.

What revenue exposure did Otsuka face?

Jynarque was a material Otsuka product, with annual global sales reported by the company in the hundreds of billions of yen in the period surrounding the litigation. The U.S. market was particularly important because Jynarque is a specialized chronic therapy with limited direct competition and high per-patient treatment value. [7]

Generic entry would likely affect revenue through:

• price erosion;
• formulary substitution;
• loss of new-patient starts;
• mandated generic substitution;
• payer pressure on branded net price; and
• reduced utilization of branded tablets after an authorized or independent generic launch.

The impact would depend on the entry date, the number of competing ANDAs, the availability of an authorized generic, and whether the generic label included the ADPKD indication.

Key Takeaways

• Otsuka Pharmaceutical v. Mylan Laboratories Limited, No. 1:22-cv-00464, was a Hatch-Waxman case involving generic tolvaptan for Jynarque.
• The principal patent risks involved ADPKD method-of-use claims, dosing regimens, and formulation-related rights.
• The original tolvaptan compound patent was not the primary commercial barrier in the 2022 dispute.
• Mylan’s Paragraph IV challenge created the standard FDA approval stay and required litigation over infringement and validity.
• A skinny-label strategy could reduce Mylan’s exposure but would also limit access to Jynarque’s principal commercial indication.
• The public record does not establish a merits judgment or disclose settlement economics and generic-entry timing.
• Jynarque and Samsca contain tolvaptan but require separate patent, label, and substitution analyses.
• Otsuka’s patent estate was commercially meaningful but more vulnerable to design-around and label-carve-out strategies than a live compound patent.

FAQs About Otsuka v. Mylan and Jynarque Patent Litigation

Did Mylan challenge Jynarque through a Paragraph IV certification?

Yes. The case was filed in response to Mylan’s ANDA and Paragraph IV patent challenge concerning generic tolvaptan.

Can a generic launch Jynarque without the ADPKD indication?

Potentially. A generic applicant may seek approval with a carved-out label, but the commercial value of the product and the risk of induced infringement depend on the remaining indications and label instructions.

Does an expired tolvaptan compound patent eliminate Otsuka’s patent protection?

No. Later-issued method-of-use, dosing, formulation, or treatment-regimen patents can continue to restrict generic approval or marketing.

Does a settlement automatically establish Mylan’s launch date?

No. The launch date depends on the settlement terms, which may be confidential, and on the status of other listed patents, regulatory exclusivity, and competing ANDA litigation.

Are biosimilars relevant to Jynarque?

No. Jynarque is a small-molecule tolvaptan product. Generic-drug rules under the ANDA pathway apply, not the biosimilar pathway under the Public Health Service Act.

References

1. U.S. District Court for the District of Delaware. (2022). Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited, No. 1:22-cv-00464, docket and pleadings.

2. U.S. Food and Drug Administration. (2018). Jynarque (tolvaptan) prescribing information. FDA.

3. 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.

5. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. USPTO.

6. U.S. Food and Drug Administration. (2009). Samsca (tolvaptan) prescribing information. FDA.

7. Otsuka Pharmaceutical Co., Ltd. (2023). Annual report and consolidated financial results. Otsuka Pharmaceutical.